Cerevance successfully completes Phase 1 clinical trial of CVN424
Category: #health  By Pankaj Singh  Date: 2019-05-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Cerevance successfully completes Phase 1 clinical trial of CVN424

Clinical stage biopharmaceutical company Cerevance has reportedly completed its Phase 1 clinical trial of CVN424, the company’s first-in-class, oral drug in development for treating Parkinson’s disease. The clinical study effectively attained its chief endpoint of safety in healthy volunteers.

The study reportedly comprised 64 healthy volunteers who were given either single dose or 7 daily doses of CVN424, extending from 1 mg to 225 mg, or placebo. There were no adverse events or clinically noteworthy changes in vital signs, laboratory values or ECG values. The drug was quickly absorbed orally and held a half-life that would support once-daily dosing, cited sources.

David H. Margolin, MD, Ph.D., Cerevance’s Senior VP for Clinical and Translational Medicine, said that CVN424’s brilliant safety profile helps authenticate the company’s approach to drug discovery and CNS target selection. The drug acts via a target that is selectively expressed by neurons significant in managing movement and was designed to attain excellent CNS penetration with nominal effects on other organs, Margolin added.

CVN424 targets novel, non-dopaminergic target protein, particularly existent in dopamine receptor D2-expressing medium spiny neurons within the basal ganglia’s indirect pathway. The drug controls the indirect pathway dependent on D2, but not the direct pathway dependent on D1. This selective aiming is developed to produce positive therapeutic effects of present treatments while preventing side effects like dyskinesia linked with dopaminergic therapies, cited sources familiar with the new therapy.

Brad Margus, CEO of Cerevance, said in a statement that the company is satisfied with the outcomes of the Phase 1 trial results for CVN424 and are keen on advancing to Phase 2. The company’s NETSseq technology platform makes use of human post-mortem brain tissue to detect targets that are selectively expressed in certain cell types and circuits or altered in disease states, enabling discovery of new treatments for neurodegenerative diseases, Margus added. 

On the basis of the positive Phase 1 outcomes, a Phase 2 study to exhibit the clinical advantages of CVN424 will be commenced later this year, reported sources.
Source Credits: https://www.businesswire.com/news/home/20190430005080/en/Cerevance-Achieves-Key-Endpoints-Phase-1-Clinical

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

EU, China ink deals to reinforce partnership on civil aviation safety
EU, China ink deals to reinforce partnership on civil aviation safety
By Pankaj Singh

The agreements will enable passengers to benefit from safer, economical, and greener air travel options The European Union (EU) has reportedly signed two agreements on civil aviation with China that are aimed at creating jobs, boost growth and bring...

Cook Medical, Ambu A/S to jointly address endoscope-related infections
Cook Medical, Ambu A/S to jointly address endoscope-related infections
By Pankaj Singh

The two firms will bring forth single-use endoscopes to patients undergoing ERCP procedures to reduce the risk associated with serious cross-contaminations. Medical device company, Cook Medical Incorporated has recently agreed to enter into a partne...

Mastercard Lyft tie up to strengthen economic security of drivers
Mastercard Lyft tie up to strengthen economic security of drivers
By Pankaj Singh

Mastercard, the financial services company announced an expanded partnership with a U.S. based transportation network company, Lyft, to bring tools to Lyft drivers for their growth in the ever-changing scenario of the gig economy. A bank account and...